Jardiance FAQ
What is Jardiance?
Jardiance (generic: empagliflozin) belongs to a class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors that are used to treat type 2 diabetes. The medication works by helping the kidneys excrete sugar (glucose) from the bloodstream.
Who Makes it?
Jardiance is manufactured by the German pharmaceutical company Boehringer Ingelheim. It was approved by the U.S. Food & Drug Administration (FDA) on August 1, 2014.
What is the Dosage?
The recommended dose of Jardiance is 10 mg once daily in the morning, taken with or without food. In patients tolerating Jardiance, the dose may be increased to 25 mg.
How Much Does it Cost?
Jardiance cost typically starts around $400 for thirty 10 mg tablets. If you are faced with having to pay for Jardiance out of pocket, be sure to look for free coupons online.
Which Side Effects has Jardiance Been Linked to?
Our lawyers are accepting potential lawsuits for people who developed the following side effects from Jardiance:
- Diabetic Ketoacidosis (DKA, Diabetic Acidosis, Metabolic Ketoacidosis, Metabolic Acidosis, Ketoacidosis)
- Kidney failure
- Urosepsis
- Pyelonephritis
Other serious side effects of Jardiance may include:
- Heart Attack (Myocardial Infarction or MI)
- Kidney Stones
- Bone Fractures / Bone Abnormalities
- Stroke
- Testicular Cancer
- Urinary Tract Infections (UTIs)
- Severe Dehydration / Fluid Imbalance
- Abnormal Weight Loss
- Hypersensitivity (Allergic Response)
- Blood Infections (Urosepsis)
- Fungal Infections
- Yeast Infections (both men and women)
- And more
What Does the FDA Say About Jardiance?
In May 2015, the FDA issued a Drug Safety Communication indicating that SGLT2 inhibitor diabetes drugs had been linked to diabetic ketoacidosis. Between March 2013 and June 6, 2014, at least 20 cases of ketoacidosis in SGLT2 inhibitor users were reported to the FDA’s Adverse Events Reporting System (FAERS).
How Can Jardiance Affect the Kidneys?
Jardiance affects normal kidney function so that sugars may be passed out the body through the urine, so patients who take the medication may face an increased risk of serious kidney problems.
Has There Been a Recall?
Despite being linked to the above serious side effects, Jardiance has not been recalled, and continues to be prescribed to unsuspecting patients across the U.S. However, Jardiance belongs to a new class of drugs and the investigation into their potential health risks is still in its early stages.
What are Jardiance Lawsuits Alleging?
Jardiance lawsuits allege that Boehringer Ingelheim failed to adequately warn doctors and patients about the risk of diabetic ketoacidosis, kidney damage and other serious side effects associated with the drug. The complaints state that had the manufacturer properly warned of these risks, patients would have been prescribed a different diabetes medication, and would have had their health monitored more closely for signs of health problems.
Have There Been any Settlements?
The first Jardiance lawsuits were only recently filed, and the proceedings are still in their early stages. It will likely be several years before Boehringer considers settling some or all of the cases. However, our lawyers feel that the manufacturer will eventually be required to pay substantial compensation as a result of their decision to place profits ahead of safety when they withheld information about the potential health risks of Jardiance.
Is There a Class Action?
No class action lawsuit has yet been filed in the Jardiance litigation, and it is doubtful that one will be entered on behalf of patients who were injured by the drug. However, if multiple lawsuits are filed alleging similar injuries, these complaints may be consolidated into a multidistrict litigation (MDL) for pretrial handling. MDLs are different from class actions, and it is generally agreed that consolidating cases instead of proceeding in a class action is a more efficient way of handling claims arising from injuries associated with pharmaceutical products.